Stephen Elledge's Harvard lab again proves fruitful with the launch of high-throughput antibody startup
After working with esteemed Harvard professor Stephen Elledge to launch TCR-focused TScan Therapeutics three years ago, the Longwood Fund approached the scientist last spring about spinning out more of his work.
Together, they launched a Cambridge, MA-based startup in December called ImmuneID, which uses Elledge’s platform to identify and target the antibody interactions that drive immune diseases, like severe allergies. And on Wednesday morning, the company unveiled a $50 million Series A round, bringing its total raise to over $70 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.